CD70 CAR T-cell therapy for brain tumors in children and young adults
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of immunotherapy called CAR T-cells that are designed to target and kill brain tumor cells that have a specific marker called CD70. It is for children and young adults with certain high-grade brain tumors, either newly diagnosed or that have come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade glioma (WHO grade III or IV) that is either newly diagnosed, recurrent, or progressive, or you have a newly diagnosed DIPG.
- Age 4 to 18 for new high-grade gliomas, and 4 to 30 for recurrent high-grade gliomas or DIPG.
- The tumor must test positive for a marker called CD70 (at least 5% of cells with some staining).
- The patient must be reasonably able to perform daily activities (score of 60% or higher on a performance scale).
- Recent blood tests show adequate bone marrow, kidney, and liver function, and no uncontrolled infections.
- For recurrent cases, the patient must have had prior radiation or chemotherapy and recovered from side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
This trial tests a new kind of cell therapy that uses your own immune cells (modified to attack cancer) to treat brain metastases. It may help people whose cancer has spread to the brain and hasn't responded to other treatments.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.